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Brief report
Increased frequencies of glutathione S-transferase (GSTM1 and GSTT1) gene
deletions in Korean patients with acquired aplastic anemia
Kyung A. Lee, Sun Hee Kim, Hee Yeon Woo, Young Joon Hong, and Hyoun Chan Cho
Patients with reduced ability to metabo-
lize environmental carcinogens or toxins
may be at risk of developing aplastic
anemia. Glutathione S-transferase (GST)
has been implicated in detoxifying muta-
genic electrophilic compounds. This
study asked whether the homozygous
gene deletions of GSTM1 and GSTT1
affect the likelihood of developing aplas-
tic anemia. The incidence of GSTM1 and
GSTT1 gene deletions was significantly
higher for aplastic anemia patients (odds
ratio [OR]: 3.1, P 5 .01 and OR: 3.1,
P 5 .004, respectively) than for healthy
controls. Among the aplastic anemia pa-
tients, 17.5% (10:57) had chromosomal
abnormalities at the time of diagnosis,
and all aplastic anemia patients with chro-
mosomal abnormalities showed GSTT1
gene deletions (P 5 .048). Individuals with
GSTM1 and GSTT1 gene deletions may
have greater susceptibility to aplastic ane-
mia. It is possible that genetic instability
or chromosomal damage due to abnor-
mal detoxification of environmental tox-
ins might have worked as an important
pathophysiologic mechanism of aplastic
anemia for patients with GSTT1 gene dele-
tions. (Blood. 2001;98:3483-3485)
© 2001 by The American Society of Hematology
Introduction
Aplastic anemia has an age-adjusted incidence of 11.0 per million
population per year in Korea and in Japan, and 2.2 in Europe and in
the United States.1 Many studies have suggested the pathophysi-
ologic role of immunologically mediated bone marrow failure, and
in practice, most patients with aplastic anemia respond favorably to
immunosuppressive therapies.2 However, this hypothesis has limi-
tations in explaining the ethnic differences in the prevalence of
aplastic anemia and the chromosomal instability associated with
aplastic anemia. Toxic environmental factors, such as drugs,
chemicals, and infections, and inherited genetic factors have been
postulated to contribute to the etiology of aplastic anemia.2 The
exact mechanism of drug-induced aplastic anemia is unknown and
may involve specific metabolic pathways as well as aberrant
immune responses. A case of anticonvulsant-induced aplastic
anemia first provided evidence of the role of drug metabolites in
aplastic anemia in humans and suggested that the increased
susceptibility to toxicity might be based on an inherited abnormal-
ity in metabolite detoxification.3 It is therefore possible that
patients with reduced ability to metabolize environmental carcino-
gens or toxins are at risk of developing aplastic anemia. An animal
study for benzene-induced hematotoxicity conducted according to
differences in xenobiotic detoxifying activities of bone marrow
stromal cells supported the hypothesis that the inherited absence of
a xenobiotic enzyme, especially the glutathione S-transferase
(GST) of the detoxification pathway, is an important determinant of
aplastic anemia.4
The m (GSTM1) and u (GSTT1) members of the GST multigene
family, which are polymorphic in humans, are involved in detoxify-
ing mutagenic electrophilic compounds, and an increased fre-
quency of these GST gene deletions has been associated with
several malignancies.5-7 The present study investigated whether
homozygous gene deletions of GSTM1 and GSTT1 increase the
incidence of aplastic anemia and explored the relationship between
the GST genotype and the chromosomal abnormalities in aplastic
anemia patients to clarify the multistep pathogenesis of aplastic
anemia based on this possible genetic predisposition.
Study design
Bone marrow (BM) samples from 57 patients with idiopathic severe
aplastic anemia (male-female ratio, 29:28; median age, 31 years; range,
5-84 years) and peripheral blood samples from 75 healthy controls
(male-female ratio, 38:37; median age, 38 years; range, 19-62 years) were
analyzed. No patients had a clinical history of occupational or drug
exposures or of viral infections such as hepatitis.
Chromosome and fluorescence in situ hybridization analysis
Cytogenetic studies on BM samples at the initial diagnosis were performed
using the standard G-banding with trypsin-Giemsa staining, and karyotypes
were interpreted according to the International System for Cytogenetic
Nomenclature.8 For 18 patients who showed no analyzable mitotic cells or
fewer than 5 metaphases in the conventional chromosome analysis, the
interphase fluorescence in situ hybridization (FISH) analysis was per-
formed using CEP 8 and 7 (Vysis, Downers Grove, IL) for the detection of
trisomy 8 and monosomy 7, the most commonly reported chromosomal
abnormalities in patients with aplastic anemia.9-10 FISH was done according
to the protocol supplied by Vysis. The cutoff levels obtained from 15 control
samples for trisomy 8 and monosomy 7 were 1.2% and 4.8%, respectively.
Multiplex polymerase chain reaction for polymorphic analysis
of GSTM1 and GSTT1
The genetic polymorphism analysis for the GSTM1 and GSTT1 genes was
determined using the multiplex polymerase chain reaction (PCR) procedure
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of Abdel-Rahman et al.11 Isolated DNA (50 ng) was amplified in a 50-mL
reaction mixture containing 30 pmol of each of the following: GSTM1
primers of 59-GAA CTC CCT GAA AAG CTA AAG C-39, 59-GTT GGG
CTC AAA TAT ACG GTG G-39 and GSTT1 primers of 59-TTC CTT ACT
GGT CCT CAC ATC TC-39, 59-TCA CCG GAT CAT GGC CAG CA-39. As
an internal control exon, 7 of the CYP1A1 genes were coamplified using the
primers 59-GAA CTG CCA CTT CAG CTG TCT-39 and 59-CAG CTG
CAT TTG GAA GTG CTC-39 in the presence of 200 mmol dNTP
(deoxynucleoside triphosphate), 5 mL 10 3 PCR buffer, 1.5 mM MgCl2,
and 2 U Taq polymerase. The PCR conditions consisted of an initial melting
temperature of 94°C (5 minutes) followed by 35 cycles of melting (94°C, 2
minutes) and annealing (59°C, 1 minute), and the extension step (72°C) of
10 minutes terminated the process. The PCR products were then analyzed
electrophoretically on an ethidium bromide–stained 2% agarose gel (Figure 1).
Results and discussion
The GSTM1 gene deletions were found in 47 (82.5%) of 57 aplastic
anemia patients and in 45 (60.0%) of 75 controls. The GSTT1 gene
deletions were found in 41 (71.9%) of 57 patients and in 34
(45.3%) of 75 controls. Most aplastic anemia patients showed
GSTM1 gene deletions (odds ratio [OR]: 3.1, 95% confidence
interval [CI], 1.4-7.1, P 5 .01), but the incidence of GSTT1 gene
deletions was also significantly higher (OR: 3.1, 95% CI, 1.5-6.4,
P 5 .004) for aplastic anemia patients. These results revealed a
significantly elevated risk of developing aplastic anemia in individu-
als with the GSTM1 and GSTT1 gene deletions (Table 1). Because
some environmental exposures involve multiple chemical sub-
strates of both GSTs, the possibility should be considered that
combined deletions of GSTM1 and GSTT1 interact to produce a
higher risk of aplastic anemia.12 Our results also showed a higher
odds ratio in patients with combined deletions of both GSTs than in
those with a single isoform.
The incidence of the GSTM1 and GSTT1 gene deletions differs
among ethnic groups, and it is higher in Koreans. In our study with
Korean subjects, the incidence of GSTT1 deletion in healthy
controls was significantly higher (45.3%) compared to those of
white Americans (20.4%), African Americans (21.8%), and Mexi-
can Americans (9.7%). The frequency of GSTM1 gene deletion was
also higher (60%) in Koreans than in whites (50%) and African
Americans (33%).13 We consider that the relatively high incidence
of aplastic anemia in Koreans could be explained by the ethnic
difference shown in the prevalence of the homozygous deleted
genotypes of GSTM1 and GSTT1.
Of the 57 aplastic anemia patients, 10 patients (17.5%) had
chromosomal abnormalities at the time of diagnosis. The chromo-
somal abnormalities were as follows: 3 cases of trisomy 8 and 1
case each of trisomy 8 and 9, t(8;21), inv(16), t(4;14), t(X;19),
del(10), and monosomy 10 (Table 2). All aplastic anemia patients
with chromosomal abnormalities showed GSTT1 gene deletions
(P 5 .048). The GSTT1 gene deletion has been associated with
carcinogen-induced chromosomal changes in lymphocytes, with
diepoxibutane being one such carcinogen.12 Recent data have also
pointed to the interactions of the Fanconi anemia phenotype and
GST, and especially the diepoxibutane-induced glutathione deple-
tion and GST inhibition, as playing an important role in the
oxidative stress in the Fanconi anemia phenotype.14 Therefore,
chromosomal damage due to abnormal detoxification of environ-
mental toxins might be an important pathophysiologic mechanism
Table 1. Frequencies of GSTM1 and GSTT1 gene deletions in aplastic
anemia patients and healthy controls
Gene deletions GSTM1 (%) GSTT1 (%)
GSTM1
and GSTT1
(%)
AA patients (n 5 57) 47 (82.5) 41 (71.9) 35 (61.4)
Odds ratio 3.1* 3.1† 3.6‡
AA patients with CA
(n 5 10)
8 (80.0)§ 10 (100)\ 8 (80.0)§
Controls (n 5 75) 45 (60.0) 34 (45.3) 23 (30.7)
AA indicates aplastic anemia; CA, chromosomal abnormalities.
*95% CI, 1.4-7.1 (P 5 .01).
†95% CI, 1.5-6.4 (P 5 .004).
‡95% CI, 1.7-7.4 (P 5 .001).
§P 5 .29.
\P 5 .048.
Figure 1. Multiplex PCR products analyzed on 2% agarose gel. The presence or
absence of GSTM1 and GSTT1 genes was detected by the presence or absence of a
band at 480 base pair (bp) (corresponding to GSTT1) and a band at 215 bp
(corresponding to GSTM1). A band at 312 bp (corresponding to 1A1 gene) was
always present and was used as an internal control to document successful PCR
amplification. Lanes 1,5, individuals with GSTT11/1 and GSTM11/1; lanes 2,7,
individuals with GSTT12/2 and GSTM11/1 alleles; lane 4, individuals with GSTT11/1
and GSTM12/2 alleles; lanes 3,6,8, individuals with deletions for both GSTM1
and GSTT1.
Table 2. Characteristics of 10 aplastic anemia patients with chromosomal abnormalities
Patient
Age,
y/Sex Karyotype at Dx Tx F/U cytogenetics
Time from
Dx (mo)
Evolution
to MDS
1 37/F 48,XX,18,19[20] BMT 48,XX,18,19[20], 46,XY[20] (BMT) 5 —
2 15/F 47,XX,18[10]/46,XX[1] IST 47,XX,18[15]/46,XX[5] 53 1*
3 65/F 47,XX,18,22pss[20] CON ND 16 —
4 41/M 46,XY,t(8;21)(q22;q22)[1]/46,XY[10] CON ND NA —
5 12/M 46,XY,inv(16)(p13.1q22)[2]/46,XY[3] CON 46,XY[20] 33 —
6 29/F 46,XX,t(X;19)(p11.2;q11)[7] CON ND 18 —
7 15/F 46,XX,t(4;14)(p10;p10)[4]/46,XX[16] BMT 46,XY[20] (BMT) 35 —
8 71/F 46,XX,del(10)(p13)[4]/46,XX[18] IST ND 41 —
9 55/M 45,X,2Y[6]/45,XY,210[3]/46,XY[11] IST ND 26 —
10 26/F 2.5% Trisomy 8 (FISH) BMT 46,XX[1]/46,XY[19] (BMT) 27 —
Dx indicates diagnosis; Tx, treatment; F/U, follow-up; MDS, myelodysplastic syndrome; F, female; BMT, bone marrow transplantation; AA, aplastic anemia; IST,
immunosuppressive therapy; CON, conservative therapy; ND, not done; M, male.
*Bone marrow findings: some clusters of megakaryocytes with nuclear atypism and immature granulocytic cells.
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of aplastic anemia for patients with GSTT1 gene deletion, although
the numbers are too small to draw a concrete conclusion.
We believe that further studies to define both the mechanism of
GSTs leading to the development of aplastic anemia and specific
substrates for GST-related aplastic anemia will be an important
approach in understanding the pathophysiology of aplastic anemia.
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